Global CAR T Cell Therapy Market, By Targeted Antigen(CD 19,CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, EGFRvlll), Therapeutic Application(Acute Lymphocytic, Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblasta, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular Carcinoma, Colorectal Cancer), and Geography - Trends, Analysis and Forecast till 2028

CAR T Cell Therapy Market – A Revolution in Cancer Treatment

Over the last few years, CAR T Cell therapy has gained wide recognition in the healthcare industry. CAR T cell is an innovative technique that involves removal of T Cells from patient’s blood before reinsertion using a genetically altered mechanism. The technology is still in the nascent stage; however, is expected to grow at double digit growth rate creating multi-billion absolute dollar opportunity for industry players in the near future. As of 2016, just over 40 companies are engaged in CAR T cell therapy market. Novartis International AG, Juno Therapeutics, and Kite Pharma Inc. are the only players that are expected to launch products by 2018. With long impending clinical trials and research activities carried out using chimeric antigen receptor cells (CAR-T) cells, these players in the pharmaceuticals industry are expected to launch various products in 2017 and commercialize them in the following two to three years.

The competition in the CAR T cell therapy market is projected to intensify following commercial launch of products of other companies by 2022. In 2015, Cellectis entered into clinical alliance with MD Anderson for development of UCARTCS1 in MM, UCART22 in ALL, UCART38 in T-cell ALL and UCART123 in a rare non-curable cancer.

The global CAR T cell therapy market is estimated to be valued at US$ 72.0 million in 2017 and is projected to expand exponentially at a CAGR of 46.1% during 2019 – 2028.

Figure 1. North America CAR T Cell Therapy Market Size and Forecast, US$ Million and Y-o-Y Growth (%)

Car-T Cell Therapy

Source: Coherent Market Insights Analysis (2017)

To have a snippet of the report, request Report Sample

CD 19 to dominate the market throughout the forecast period

Acute lymphoblastic leukemia (ALL) is highly prevalent among children. Adults account for over 40% cases of ALL. Changing lifestyle along with increasing incidence of cancer among children necessitates an effective treatment approach in the healthcare industry for effective treatment of the same. As a result, CAR- T cell therapy has emerged as one of the potential therapies to address this issue. CD-19 marker is highly effective in tackling the growing incidence problem of ALL. The CD-19 antigen CAR T Cell segment is expected to be valued at US$ 1.2 billion by 2023 and is expected to continue dominate the market (in terms of revenue) through the remainder of the forecast period.

North America to retain its dominance in the CAR T cell therapy market through 2028

North America is home to state of the art R&D labs along and is characterized by high prevalence rate of blood cancer. Each year, over 171,000 people are diagnosed with blood cancer in the U.S. Of these, around 46% suffer from lymphoma (U.S. Leukemia & Lymphoma Society), thereby creating major market opportunity for CAR T cell therapy industry players to capitalize on highly lucrative growth opportunities in the region. North America is expected to account for 52.5% of overall market share by 2020. Kite Pharma Inc. along with Novartis International AG are expected to gain significant market share in the region, as these companies have already applied for U.S. Biologics License Application (BLA). Moreover, these companies have established dedicated manufacturing sites for CAR-T cell therapy products; Kite Pharma established its 43,500 square foot plant in the U.S. for production of CAR-T cell products. The plant is expected to produce up to 5,000 patient therapy products in 2018. In 2016, Juno Therapeutics invested US$ 20 million to set up of CAR-T cell products manufacturing facility in the U.S. These companies are analyzed to greatly benefit from first mover advantage.

Europe is expected to second-most prominent market (in terms of revenue) through 2023, post which it would lose it position to Asia Pacific. Asia Pacific market is expected to grow at the fastest rate, expanding at a CAGR of 62.5% between 2019 and 2028. Japan and China are the key regions in Asia Pacific that market players would focus on during the latter half of the forecast period to pave a way for higher return on investment (ROI).

Diversification of CAR T Cell in other therapeutics application is expected to create lucrative market opportunities for market players

Currently, Juno Therapeutics along with Kite Pharma and Novartis are working on CD 19 antigen—responsible for blood cancers. These companies also have a product roadmap to commercialize products based on CD 30 and 22 responsible for solid cancers. FDA approval of these products by 2025 is projected to drive the market growth over the latter half of the forecast period.

(*The forecast period for the total CAR T Cell therapy market is : 2017 – 2028; However, following expected launch of products across various years, the market value and growth rate for the segments covering these products has been analyzed from the period 2019 onwards)

CAR T cell therapy has been a major buzzword for a while, owing to its effectiveness in treating blood cancer. These are the genetically engineered receptors that targets surface molecules in patient’s immune system. T cells are collected from patients and are genetically engineered in the laboratory in order to multiply them by millions. These T cells are further injected in patients to offer immunity and guard against recurrence of tumorous cells.

Market Dynamics

CAR T cell therapy is expected to be a game changer post its commercialization creating revenue opportunities for players in the CAR T cell therapy market. Moreover, it is expected to help with effective diagnosis of acute lymphoblastic leukemia (ALL) in B cells of children. Introduction of the drug is expected to be especially beneficial for leukemia patients. According to the U.S. National Cancer Institute, over 340,000 people in the U.S., suffered from leukemia in 2015, with an estimated 1.5% of the population in the country expected to be detect with leukemia once in their lifetime. Growing prevalence rate and increasing demand for effective treatment modalities is expected to pave way for market growth over the forecast period.

The CAR T cell therapy market is expected to be highly consolidated over the next few years, with the three major players accounting for around half of the overall market revenue share. This novel therapeutic application is expected to create lucrative profit margins for industry players across the value chain, ranging from manufacturers to distributors and end-use hospitals.

Market Taxonomy

This report segments the CAR T cell therapy market on the basis of antigen type, and therapeutic applications. On the basis of antigen, CAR T cell therapy market is segmented as CD 19, CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, EGFRvlll, and others.

On the basis of therapeutic applications, CAR T cell therapy market is segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, non-hodgkin leukemia, multiple myeloma, pancreatic cancer, neuroblasta, breast cancer, acute myeloid leukemia, hepatocellular carcinoma, colorectal cancer, and other therapeutic applications.

Key features of the study:

  • This report provides in-depth analysis of the CAR T cell therapy market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR) (%) for the forecast period (2017 – 2028)
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides valuable insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • The report takes into account critical limiting factors such as accuracy issues and need for calibrating the device several times a day while analyzing the market value and growth (%) during the forecast period
  • It includes insights on population dynamics, number of dental clinic centers, and demand for CAR T Cell Therapy across the globe.
  • It profiles leading players in the global CAR T Cell Therapy market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies and future plans
  • Key companies covered as a part of this study include Juno Therapeutics, Kite Pharma Inc., Novartis International AG, Bellicum Pharmaceuticals Inc., Celgene Corporation, and Cellectis.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future product launch, technology upgrade, market expansion, and marketing tactics
  • The global CAR T Cell Therapy market report caters to various stakeholders in this industry, including investors, raw material manufacturer, contract manufacturer, device manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would greatly benefit in decision making through the various strategy matrices used in analyzing the CAR T Cell Therapy market.

Detailed Segmentation:

  • Global CAR T Cell Therapy Market, By Targeted Antigen:
    • CD 19
    • CD 20
    • GD2
    • CD22
    • CD30
    • CD33
    • HER1
    • HER2
    • Meso
    • EGFRvlll
    • Others
  • Global CAR T Cell Therapy Market, By Therapeutic Application:
    • Acute Lymphocytic Leukemia
    • Chronic Lymphocytic Leukemia
    • Non Hodgkin Leukemia
    • Multiple Myeloma
    • Pancreatic Cancer
    • Neuroblasta
    • Breast Cancer
    • Acute Myeloid Leukemia
    • Hepatocellular Carcinoma
    • Colorectal Cancer
    • Others
  • Global CAR T Cell Therapy Market, By Geography:
    • North America
      • North America CAR T Cell Therapy Market, By Targeted Antigen:
        • CD 19
        • CD 20
        • GD2
        • CD22
        • CD30
        • CD33
        • HER1
        • HER2
        • Meso
        • EGFRvlll
        • Others
      • North America CAR T Cell Therapy Market, By Technique:
        • Acute Lymphocytic Leukemia
        • Chronic Lymphocytic Leukemia
        • Non Hodgkin Leukemia
        • Multiple Myeloma
        • Pancreatic Cancer
        • Neuroblasta
        • Breast Cancer
        • Acute Myeloid Leukemia
        • Hepatocellular Carcinoma
        • Colorectal Cancer
        • Others
    • Europe
      • Europe CAR T Cell Therapy Market, By Targeted Antigen:
        • CD 19
        • CD 20
        • GD2
        • CD22
        • CD30
        • CD33
        • HER1
        • HER2
        • Meso
        • EGFRvlll
        • Others
      • Europe CAR T Cell Therapy Market, By Technique:
        • Acute Lymphocytic Leukemia
        • Chronic Lymphocytic Leukemia
        • Non Hodgkin Leukemia
        • Multiple Myeloma
        • Pancreatic Cancer
        • Neuroblasta
        • Breast Cancer
        • Acute Myeloid Leukemia
        • Hepatocellular Carcinoma
        • Colorectal Cancer
        • Others
    • Asia Pacific
      • Asia Pacific CAR T Cell Therapy Market, By Targeted Antigen:
        • CD 19
        • CD 20
        • GD2
        • CD22
        • CD30
        • CD33
        • HER1
        • HER2
        • Meso
        • EGFRvlll
        • Others
      • Asia Pacific CAR T Cell Therapy Market, By Technique:
        • Acute Lymphocytic Leukemia
        • Chronic Lymphocytic Leukemia
        • Non Hodgkin Leukemia
        • Multiple Myeloma
        • Pancreatic Cancer
        • Neuroblasta
        • Breast Cancer
        • Acute Myeloid Leukemia
        • Hepatocellular Carcinoma
        • Colorectal Cancer
        • Others
    • Latin America
      • Latin America CAR T Cell Therapy Market, By Targeted Antigen:
        • CD 19
        • CD 20
        • GD2
        • CD22
        • CD30
        • CD33
        • HER1
        • HER2
        • Meso
        • EGFRvlll
        • Others
      • Latin America CAR T Cell Therapy Market, By Technique:
        • Acute Lymphocytic Leukemia
        • Chronic Lymphocytic Leukemia
        • Non Hodgkin Leukemia
        • Multiple Myeloma
        • Pancreatic Cancer
        • Neuroblasta
        • Breast Cancer
        • Acute Myeloid Leukemia
        • Hepatocellular Carcinoma
        • Colorectal Cancer
        • Others
    • Middle East
      • Middle East CAR T Cell Therapy Market, By Targeted Antigen:
        • CD 19
        • CD 20
        • GD2
        • CD22
        • CD30
        • CD33
        • HER1
        • HER2
        • Meso
        • EGFRvlll
        • Others
      • Middle East CAR T Cell Therapy Market, By Technique:
        • Acute Lymphocytic Leukemia
        • Chronic Lymphocytic Leukemia
        • Non Hodgkin Leukemia
        • Multiple Myeloma
        • Pancreatic Cancer
        • Neuroblasta
        • Breast Cancer
        • Acute Myeloid Leukemia
        • Hepatocellular Carcinoma
        • Colorectal Cancer
        • Others
    • Africa
      • Africa CAR T Cell Therapy Market, By Targeted Antigen:
        • CD 19
        • CD 20
        • GD2
        • CD22
        • CD30
        • CD33
        • HER1
        • HER2
        • Meso
        • EGFRvlll
        • Others
      • Africa CAR T Cell Therapy Market, By Technique:
        • Acute Lymphocytic Leukemia
        • Chronic Lymphocytic Leukemia
        • Non Hodgkin Leukemia
        • Multiple Myeloma
        • Pancreatic Cancer
        • Neuroblasta
        • Breast Cancer
        • Acute Myeloid Leukemia
        • Hepatocellular Carcinoma
        • Colorectal Cancer
        • Others
  • Company Profiles
    • Novartis International AG *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
      • Future Plans
    • Kite Pharma Inc.
    • Juno Therapeutics
    • Bellicum Pharmaceuticals, Inc.
    • Celgene Corporation
    • Cellectis

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet By Targeted Antigen
      • Market Snippet By Therapeutic Application
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Regulatory Scenario
      • Industry Trend
      • Epidemiology/Prevalence/Incidence
      • Merger and Acquisitions
      • New Product Approvals/Launch
  4. Global Car T Cell Therapy Market, By Targeted Antigen, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2028 (%)
      • Y-O-Y Growth Analysis, 2017 - 2028
      • Segment Trends
    • CD 19
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • CD 20
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • GD2
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • CD22
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • CD30
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • CD33
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • HER1
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • HER2
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • Meso
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • EGFRvlll
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  5. Global Car T Cell Therapy Market, By Therapeutic Application, 2017 - 2028 (USD Million)
    • Introduction
      • Market Share Analysis, 2017 and 2028 (%)
      • Y-O-Y Growth Analysis, 2017 - 2028
      • Segment Trends
    • Acute Lymphocytic Leukemia
      • Introduction
      • Market Share Analysis, 2017 and 2028 (%)
      • Y-O-Y Growth Analysis, 2017 - 2028
    • Chronic Lymphocytic Leukemia
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • Non Hodgkin Leukemia
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • Multiple Myeloma
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • Pancreatic Cancer
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • Neuroblasta
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • Breast Cancer
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • Acute Myeloid Leukemia
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • Hepatocellular Carcinoma
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • Colorectal Cancer
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  6. Global Car T Cell Therapy Market, By Regions, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2017 and 2028 (%)
      • Y-O-Y Growth Analysis, For Regions, 2017 - 2028
    • North America
      • Market Share Analysis, By Segments, 2017 and 2028 (%)
      • Y-O-Y Growth Analysis, By Segments, 2017 - 2028
        • Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
        • Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
    • Europe
      • Market Share Analysis, By Segments, 2017 and 2028 (%)
      • Y-O-Y Growth Analysis, By Segments, 2017 - 2028
        • Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
        • Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
    • Asia Pacific
      • Market Share Analysis, By Segments, 2017 and 2028 (%)
      • Y-O-Y Growth Analysis, By Segments, 2017 - 2028
        • Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
        • Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
    • Latin America
      • Market Share Analysis, By Segments, 2017 and 2028 (%)
      • Y-O-Y Growth Analysis, By Segments, 2017 - 2028
        • Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
        • Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
    • Africa
      • Market Share Analysis, By Segments, 2017 and 2028 (%)
      • Y-O-Y Growth Analysis, By Segments, 2017 - 2028
        • Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
        • Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
    • Middle East
      • Market Share Analysis, By Segments, 2017 and 2028 (%)
      • Y-O-Y Growth Analysis, By Segments, 2017 - 2028
        • Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
        • Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
  7. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
    • Company Profiles
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Kite Pharma Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Juno Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Bellicum Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Celgene Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Cellectis
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 90 market data tables and 40 figures on "Car T Cell Therapy Market - Global forecast to 2024”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

sales@coherentmarketinsights.com

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.